Phase 1a data in 16 patients with recurrent glioblastoma established a recommended dose for expansion of LP-184 for a planned phase 1b/2a combination trial.
|Videos|October 9, 2017
Rate of Uninsured Cancer Patients Dropped in Medicaid Expansion States
Author(s)Fumiko Chino, MD
This video examines changes in insurance status after implementation of the Affordable Care Act among cancer patients who received radiation therapy.
Advertisement
In this video, Fumiko Chino, MD, of Duke University Medical Center in Durham, North Carolina, discusses a study that examined changes in insurance status among cancer patients who received radiation therapy after implementation of the Affordable Care Act, both in States that expanded Medicaid and in those that did not.
Chino presented the results of the study (
Advertisement
Related to this article
The FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.
The FDA approved pimicotinib for TGCT based on phase 3 MANEUVER data showing durable responses and improved pain, stiffness, and function.
Real-world data showed a 68% 12-month high-grade recurrence-free survival rate with hyperthermic mitomycin C in patients with BCG-unresponsive NMIBC.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
3
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
4
Evolving Perioperative Treatment Landscape for Resectable Gastric and Gastroesophageal Junction Cancers: A Q&A with Dr Nataliya Uboha
5